UnknownPhase 2

Trimetazidine Therapy in Hypertrophic Cardiomyopathy

United Kingdom90 participantsStarted 2012-04

Plain-language summary

Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition that causes breathlessness, chest pain and fatigue. There are few treatments available. The investigators have recently shown that a drug called perhexiline reduced symptoms and improved exercise capacity in patients with HCM. This change appears to be driven by alterations in myocardial energy metabolism. The aim of this trial is to test a similar drug, trimetazidine, in a group of symptomatic patients with non-obstructive HCM. HYPOTHESIS: trimetazidine will improve symptoms, peak oxygen consumption, cardiac function and arrhythmia burden in medically refractory symptomatic patients with non-obstructive HCM.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Non-obstructive hypertrophic cardiomyopathy (gradient \<30 mmHg at rest) * NYHA (New York Heart Association) Class ≥ 2 * Peak VO2 (maximal oxygen consumption) ≤80% predicted for age and gender * Heart rate \< 90/minute at rest Exclusion Criteria: * Diabetes Mellitus * Abnormal renal function (GFR\<60ml/min) or hepatic impairment * Female who is pregnant, lactating or planning pregnancy during the course of the study

What they're measuring

Peak oxygen consumption

Timeframe: 3 months

Trial details

NCT IDNCT01696370

SponsorUniversity College, London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-04

Contact for this trial

Perry M Elliott, MBBS MD

020 3456 7898 p.elliott@ucl.ac.uk

View on ClinicalTrials.gov More Hypertrophic Cardiomyopathy trials